Eli Lilly's shares have increased by about 10% over the past month. Clinical progress in the past few weeks has helped solidify its lead in the weight loss market. The company's prospects remain ...
Abbott Laboratories has a tremendous track record for stability and dividend growth. AbbVie offers something for income, growth, and value investors. Eli Lilly has a fast-growing dividend plus great ...
MarketBeat on MSN
What Does the Future Hold for Eli Lilly?
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely the hottest medical sector story in 2024. With its offering of tirzepatide ...
Eli Lilly's GLP-1 drug portfolio should power the business for at least the next decade. But the market appears well aware of the company's weight loss drug success. Weight loss drugs are set to ...
Eli Lilly continues to do what it does best, which is to capture the obesity and type 2 diabetes treatment markets at an extremely rapid pace. So, sales of its flagship franchise called tirzepatide ...
The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback